Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Cytologically or histologically confirmed diagnosis of 1 of the following:
• * Metastatic breast cancer
• * Colorectal cancer
• * Gastric cancer
• * Lung cancer
• * Ovarian cancer
• * Pancreatic cancer
• * Hormone-refractory prostate cancer
• Scheduled to undergo chemotherapy for ≥ 3 months
• * Chemotherapy for colorectal, gastric, lung, ovarian, or pancreatic cancer may be administered in the neoadjuvant, adjuvant, or palliative setting
• History of deep vein thrombosis or pulmonary embolism allowed if treatment and secondary prevention of the last episode was completed prior to study entry
• * Negative baseline bilateral compression ultrasonography
• PATIENT CHARACTERISTICS:
• Life expectancy \> 3 months
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• More than 6 weeks since prior chemotherapy\*
• * Hormonal therapy alone is not considered chemotherapy
• More than 4 weeks since prior major surgery, including surgery for cancer
• * Minor surgery (e.g., implant of a port-a-cath) within the past 4 weeks allowed
• No concurrent major surgery, including surgery for cancer, during the observation period
• Radiotherapy before or during the observation period allowed
• Concurrent chemotherapy\* in combination with additional hormonal therapy allowed
• Concurrent treatment (with the exception of antithrombotic therapy) in any other clinical trial allowed
• No concurrent or scheduled use of thromboprophylaxis or any anticoagulant therapy, including any of the following:
• * Parenteral anticoagulants (e.g., heparin, low molecular-weight heparin, or other agents, such as fondaparinux or bivalirudin)
• * Oral anticoagulants (e.g., vitamin K antagonists)
• * Thrombolytic agents
• * Chronic treatment with antiplatelet agents, such as low-dose aspirin (≤ 300 mg/day) or clopidogrel allowed NOTE: \*Chemotherapy is defined as treatment with any antineoplastic agent, including biologicals